Wolf, Greenfield & Sacks, P.C. | 600 Atlantic Avenue | Boston, Massachusetts 02210 | 617.646.8000 | 617.646.8646 fax | wolfgreenfield.com Recent Developments.

Slides:



Advertisements
Similar presentations
Second level — Third level Fourth level »Fifth level CLS Bank And Its Aftermath Presented By: Joseph A. Calvaruso Orrick, Herrington & Sutcliffe LLP ©
Advertisements

Orlando, Florida | Mayo v. Prometheus by:Jon M. Gibbs Lowndes, Drosdick, Doster, Kantor and Reed PA.
Industrial Property the Patent system
Diagnostics: Patent Eligibility and the Industry Perspective
© 2011 Sterne, Kessler, Goldstein, & Fox P.L.L.C. All Rights Reserved. Patenting Biomarkers and Diagnostic Methods Neil P. Shull, Ph.D., J.D. S TERNE,
Mayo – The Bell Tolled or, It’s the End of the World as We Know It (And I Feel Fine) May 3, 2012 AIPLA Biotechnology Committee Webinar James J. Kelley.
What is Happening to Patent Eligibility and What Can We Do About It? June 24, 2014 Bruce D. Sunstein Denise M. Kettelberger, Ph.D. Sunstein Kann Murphy.
1 1 AIPLA 1 1 American Intellectual Property Law Association Patentable Subject Matter in the US AIPPI-Symposium Zeist 13 March 2013 Raymond E. Farrell.
1 Bioinformatics Practice Considerations October 20, 2011 Ling Zhong, Ph.D.
© 2011 Edwards Wildman Palmer LLP & Edwards Wildman Palmer UK LLP Patenting Methods of Medical Treatment in the United States AIPPI 2011 Forum/ExCo Peter.
PATENTABLE SUBJECTS IN THE INTERNET OF THINGS ALICIA SHAH.
11 Post-Bilski Case Law Update Remy Yucel Director, Central Reexamination Unit.
1 1 AIPLA Firm Logo American Intellectual Property Law Association CURRENT STATE OF 35 USC 101: “USPTO GUIDELINES ON PRODUCTS OF NATURE, LAWS OF NATURE,
Mayo v. Prometheus Decided March 20, 2012 Roberte Makowski, Ph.D., J.D. Hans Sauer, Ph.D., J.D.
AIPLA Biotechnology Committee Webinar: Mayo v. Prometheus: Did the Bell Toll for Personalized Medicine Patents? Prof. Joshua D. Sarnoff DePaul U. College.
More on Section 101 Patent Law Prof. Merges
“REACH-THROUGH CLAIMS”
* Statements of fact and opinions expressed are those of the speaker individually and are not the opinion or position of Research In Motion Limited or.
EVALUATING SUBJECT MATTER ELIGIBILITY UNDER 35 U. S. C
Patents Copyright © Jeffrey Pittman. Pittman - Cyberlaw & E- Commerce 2 Legal Framework of Patents The U.S. Constitution, Article 1, Section 8:
1 TC 1600 Subject Matter Eligibility Under 35 USC § 101 Andrew Wang SPE 1631 (571)
Patents 101 April 1, 2002 And now, for something new, useful and not obvious.
2015 AIPLA IP Practice in Europe Committee June, 2015 Phil Swain Foley Hoag LLP Boston, MA - USA The Effect of Alice v CLS Bank on patent subject matter.
1 1 1 AIPLA Firm Logo American Intellectual Property Law Association UPDATE ON SUBJECT MATTER ELIGIBILITY, CLS BANK AND ITS AFTERMATH Joseph A. Calvaruso.
1 1 AIPLA Firm Logo American Intellectual Property Law Association Myriad Guidance for Biotechnology and Chemical Practice Joerg-Uwe Szipl Griffin and.
Medical Device Partnership: USPTO Interim Eligibility Guidance Michael Cygan, USPTO June 2, 2015.
Examiner Guidelines After Alice Corp. August 21, 2014 How Much “More” is “Significantly More”?
Patentable Subject Matter and Design Patents,Trademarks, and Copyrights David L. Hecht, J.D., M.B.A, B.S.E.E.
Utility Requirement in Japan Makoto Ono, Ph.D. Anderson, Mori & Tomotsune Website:
Biotechnology/Chemical/Pharmaceutical Customer Partnership: Recent Examiner Training and Developments Under 35 USC § 101 Drew Hirshfeld Deputy Commissioner.
Biotechnology Chemistry Pharmaceutical Partnership Meeting September 8, 2010 D. Benjamin Borson, M.A., J.D., Ph.D. Borson Law Group, PC Copyright, Borson.
© Kolisch Hartwell 2014 All Rights Reserved, Page 1 Oregon Best Fest September 2014 Peter D. Sabido Intellectual Property Attorney Kolisch Hartwell, P.C.
Public Policy Considerations and Patent Eligible Subject Matter Relating to Diagnostic Inventions Disclaimer: Any views expressed here are offered in order.
Judicially Created Diversity in Patent Law Norman Siebrasse Professor of Law University of New Brunswick, Canada.
PATENTSHIP. What is a Patent?  Patent  is an exclusive and monopoly right  to use the patented invention  for a limited area and time (20 Years) 
Impact of Myriad Decisions on Patent Eligibility of Biotechnology Inventions in Australia and the US.
© 2011 Barnes & Thornburg LLP. All Rights Reserved. This page, and all information on it, is the property of Barnes & Thornburg LLP which may not be reproduced,
Post-Prometheus Interim Examination Guidelines Daphne Lainson Smart & Biggar AIPLA 1.
11 PATENT LAW Randy Canis CLASS 15 Case Law Update.
Post-Bilski Patent Prosecution IP Osgoode March 13, 2009 Bob Nakano McCarthy Tétrault LLP.
Introduction to Patents Anatomy of a Patent & Procedures for Getting a Patent Margaret Hartnett Commercialisation & IP Manager University.
Patentability Considerations in the 3-D Structure Arts Patentability Considerations in the 3-D Structure Arts Michael P. Woodward Supervisory Patent Examiner.
Trilateral Project WM4 Report on comparative study on Examination Practice Relating to Single Nucleotide Polymorphisms (SNPs) and Haplotypes. Linda S.
Josiah Hernandez What can be Patented. What can be patented A patent is granted to anyone who “invents or discovers any new and useful process, machine,
LAW OF COMPUTER TECHNOLOGY FALL 2015 © 2015 MICHAEL I. SHAMOS Business Method Patents Michael I. Shamos, Ph.D., J.D. Institute for Software Research School.
1. 35 USC § 101: Statutory Requirements and Four Categories of Invention August 2015 Office of Patent Legal Administration United States Patent and Trademark.
INTERIM GUIDELINES FOR PATENT SUBJECT MATTER ELIGIBILITY ARDIN MARSCHEL SPE AU 1631 (571)
1 1 AIPLA Firm Logo American Intellectual Property Law Association More Fun with A Prosecution Perspective on the Protection of Computer Implemented.
Mayo v. Prometheus Labs – The Backdrop June 12, 2012 © 2012, all rights reserved.
Patentable Subject Matter Donald M. Cameron. 2 Patents: The Bargain Public: gets use of invention after patent expires Inventor/Owner: gets limited monopoly.
© 2008 International Intellectual Property June 16, 2009 Class 2 Introduction to Patents.
Myriad The Future of DNA Claims Mercedes Meyer, Ph.D., JD AIPLA 1.
© 2012 Cooley LLP, Five Palo Alto Square, 3000 El Camino Real, Palo Alto, CA The content of this packet is an introduction to Cooley LLP’s capabilities.
Fundamentals of Intellectual Property
What is Patentable Subject Matter? Dan L. Burk Chancellor’s Professor of Law University of California, Irvine.
Interim Guidance on Patent Subject Matter Eligibility Raul Tamayo, USPTO July 13, 2015.
A Madness to the Method? The Future of Method Patents After Bilski Brian S. Mudge July 19, 2010.
Surviving Subject Matter in the Post Prometheus/Myriad World Lesley Rapaport LRR Patent Law Denise M. Kettelberger Sunstein Kann Murphy & Timers LLP Carmela.
Jody Blanke, Professor Computer Information Systems and Law 1.
Patents 101 March 28, 2006 And now, for something new, useful and not obvious.
The Challenge of Biotech Patent Eligibility in the United States:
Alexandria, Virginia July 21, 2014
9th class: Patent Protection
ChIPs Global Summit, September 15, 2016
Recent USPTO Developments on Subject Matter Eligibility
Comparing subject matter eligibility in us and eu
Patentable Subject Matter
Subject Matter Eligibility
A tutorial and update on patentable subject matter
Presentation transcript:

Wolf, Greenfield & Sacks, P.C. | 600 Atlantic Avenue | Boston, Massachusetts | | fax | wolfgreenfield.com Recent Developments Concerning Patent-Eligible Subject Matter Yale University September 11, 2014 Down the Rabbit Hole …..

© 2014 Wolf, Greenfield & Sacks, P.C. All rights reserved. Supreme Court IP Cases  Mayo v. Prometheus  Aereo  Alice  Nautilus  Limelight  Octane  Pom Wonderful 2

© 2014 Wolf, Greenfield & Sacks, P.C. All rights reserved. 3

Economics  Industries that directly rely on patents and trademarks support about 40 million jobs - about 25% of all jobs in the U.S.  These industries account for approximately $5 trillion – about 35% of the U.S. GDP  AUTM Licensing Activity Survey 2013 University and Non-Profit Patent Licensing Impact as much as: $388 billion on U.S. gross domestic product $836 billion on U.S. gross industrial output* *Biotechnology Industry Organization 4

© 2014 Wolf, Greenfield & Sacks, P.C. All rights reserved. 35 U.S. Code § Inventions patentable Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title. 5

© 2014 Wolf, Greenfield & Sacks, P.C. All rights reserved. Judicially Created Exceptions  Laws of Nature/Scientific Discoveries  Applied Force equals the mass of an object multiplied by its acceleration  Energy content of an object equals its mass multiplied by the square of the speed of light  Levels of drug metabolites in human body 6

© 2014 Wolf, Greenfield & Sacks, P.C. All rights reserved. Judicially Created Exceptions (Con’t.) 7

© 2014 Wolf, Greenfield & Sacks, P.C. All rights reserved. Question Presented  Whether claims to computer-implemented inventions—including claims to systems and machines, processes, and items of manufacture—are directed to patent-eligible subject matter within the meaning of 35 U.S.C. § 101 as interpreted by this Court.  Focus on computer-implemented scheme but decision applies across technologies. 8

© 2014 Wolf, Greenfield & Sacks, P.C. All rights reserved. Alice v. CLS – “ Technology”  Computer-implemented scheme for mitigating settlement risk.  Third party intermediary maintains “shadow credit record” and “shadow debit record” for each transacting party.  For each proposed transaction, third party checks if any party would end up owing more than being owed. Assets Liabilities 9

© 2014 Wolf, Greenfield & Sacks, P.C. All rights reserved. Technology in Prometheus Patent  Use of thiopurine drugs to treat an immune-mediated GI disorder claim:  A method of optimizing therapeutic efficacy for treatment of an immune-mediated GI disorder, comprising: a)administering a drug providing 6-thioguanine to a subject...., and b)determining the level of 6-thioguanine in said subject...., wherein the level of 6-thioguanine less than about 230 pmol 8x10 8 RBCs indicates a need to increase... and wherein the level of 6-thioguanine greater than about 400 pmol 8x10 8 RBCs indicates a need to decrease

© 2014 Wolf, Greenfield & Sacks, P.C. All rights reserved. Issue before U.S. Supreme Court  Do the claims do significantly more than simply describe the natural relations in which thiopurine compounds are metabolized by the body?  Conclusion: “steps are not sufficient to transform unpatentable natural correlations into patentable applications of those regularities”  A patent cannot “simply recite a law of nature and then add the instruction apply the law.” 11

© 2014 Wolf, Greenfield & Sacks, P.C. All rights reserved.  Mayo Framework applies to all judicial exceptions. 1)Is invention directed to law of nature, natural phenomena, or abstract idea? 2)If so, search for an “inventive concept” that ensures the claim amounts to “significantly more” than the law of nature, natural phenomena, or abstract idea itself.  Mayo Framework applies to all claim types. Supreme Court Two-Part Test to Determine Subject-Matter Eligibility 12

© 2014 Wolf, Greenfield & Sacks, P.C. All rights reserved. Step One  Is the invention Directed to a Judicial Exception?  Law of Nature  Natural Phenomenon  Abstract Ideas  Claims are Directed to the Concept of “Intermediated Settlement” 13

© 2014 Wolf, Greenfield & Sacks, P.C. All rights reserved. Step One (Con’t.)  Intermediated Settlement is a Fundamental Economic Concept  “long prevalent in our system of commerce”  “building blocks of the modern economy”  “taught in any introductory finance class”  “long standing economic practice”  Fundamental Economic Concepts can be Abstract Ideas  So, YES! 14

© 2014 Wolf, Greenfield & Sacks, P.C. All rights reserved. Step Two  Is there “inventive concept” that amounts to “significantly more” than the judicial exception?  More than mere conventional activity  Can be either a new element or a combination of old elements  Insufficient  Generic computer Implementation (Alice)  Well-understood, routine, conventional activities  Limiting use to particular technological environment 15

© 2014 Wolf, Greenfield & Sacks, P.C. All rights reserved. Step Two (Con’t.)  Possibly Sufficient  Improving existing technological process  Improving another technology or technical field  Improving the functioning of computer itself 16

© 2014 Wolf, Greenfield & Sacks, P.C. All rights reserved. What Alice v. CLS Tells Us  The abstract idea exception is broader than mathematical formulas and preexisting, fundamental truths  No categorical exclusion of business methods.  Concurrence: Sotomeyor, Ginsburg, Breyer would have created business method exception. 17

© 2014 Wolf, Greenfield & Sacks, P.C. All rights reserved. Abstract Idea Preexisting, Fundamental Truths Mathematical Algorithms/Formulas Fundamental Economic Practice Methods of Organizing Human Activities What is an Abstract Idea? 18

© 2014 Wolf, Greenfield & Sacks, P.C. All rights reserved. What Alice v. CLS Does Not Tells Us:  “In any event, we need not labor to delimit the precise contours of the ‘abstract idea’ category in this case.”  What standards of novelty and non- obviousness for 101 purposes?  Same as 102 and 103?  Since the abstract idea is considered known, is this like a 103 rejection without a reference? 19

© 2014 Wolf, Greenfield & Sacks, P.C. All rights reserved. USSN: 13/193,421, allowed 12/2013  1.A method of diagnosing, aiding in diagnosing or predicting risk of developing early onset neonatal sepsis (EONS) in a newborn subject, comprising: (a) determining if switching of an Hp 0-0 phenotype to an Hp 1-1, an Hp 2-2 or an Hp 1-2 phenotype has occurred in the newborn subject;  and (b) diagnosing or aiding in diagnosing the newborn subject as having EONS, or predicting that the newborn subject is at increased risk of developing EONS, if switching of an Hp 0-0 phenotype to an Hp 1-1, an Hp 2-2 or Hp 1-2 phenotype has occurred.  Canceled:  36.(New) A method of diagnosing, aiding in diagnosing or predicting risk of developing early onset neonatal sepsis (EONS) in a newborn subject, comprising: 20

© 2014 Wolf, Greenfield & Sacks, P.C. All rights reserved. USSN: 13/193,421, allowed 12/2013 (cont’d)  (a)detecting haptoglobulin and haptoglobulin-related protein (Hp&HpRP) immunoreactivity in a biological sample of the newborn subject; and  (b)diagnosing or aiding in diagnosing the newborn subject as having EONS, or predicting that the newborn subject is at increased risk of developing EONS, if Hp&HpRP immunoreactivity is detected in the biological sample. 21

© 2014 Wolf, Greenfield & Sacks, P.C. All rights reserved. USSN: 13/131,787, recently allowed 1.An agent comprising i)a first peptide comprising the amino acid sequence of SEQ ID NO: 13, ii)a second peptide comprising the amino acid sequence of SEQ ID NO: 14, and iii)a third peptide comprising the amino acid sequence of SEQ ID NO: